Castle Biosciences says ACG 2026 data show TissueCypher flags Barrett’s progression risk beyond biopsy findings
Castle Biosciences announced new TissueCypher data in Barrett’s esophagus scheduled for presentation at the ACG 2026 meeting in Nashville. Across two case reports and a multi-center study, the test flagged higher progression risk than biopsy findings suggested, prompting earlier escalation of care. Clinicians changed s